stockrowBicycle Therapeutics PLC Sponsored ADR
BCYCBicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024.
- Revenue
- +190.2%
- EPS
- +82.4%
- Free cash flow
- +43.5%
Quarter to September 2026, against a year earlier
Follow BCYC
Alert me
Bicycle Therapeutics PLC Sponsored ADR (BCYC) Piotroski F-score
Bicycle Therapeutics PLC Sponsored ADR's Piotroski F-score for fiscal 2025 is 2 out of 9: 2 of nine tests of profitability, leverage and efficiency passed, down from 4 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 2 | (2.00) |
| FY2024 | 4 | 0.00 |
| FY2023 | 4 | 2.00 |
| FY2022 | 2 | (2.00) |
| FY2021 | 4 | 3.00 |
| FY2020 | 1 | (2.00) |
| FY2019 | 3 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (26.15%) | (21.78%) | Fail | 0 |
| Positive operating cash flow | (249.67m) | (164.72m) | Fail | 0 |
| Rising return on assets | (26.15%) | (21.78%) | Fail | 0 |
| Cash flow above net income | (30.71m) | 4.31m | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 11.98 | 13.81 | Fail | 0 |
| No new shares issued | 69,280,000 | 58,208,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.09 | 0.05 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 2 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| CGEN Compugen Ltd. compare | 7 |
| MDWD MediWound Ltd. compare | 5 |
| WHWK Whitehawk Therapeutics, Inc. compare | 4 |
| TRDA Entrada Therapeutics, Inc. compare | 3 |
| UPB Upstream Bio, Inc. compare | 2 |
| BCYC Bicycle Therapeutics PLC Sponsored ADR | 2 |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | — |
| IVVD Invivyd, Inc. compare | — |
| ACOG Alpha Cognition Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover